NAFLD is considered the most predominant form of chronic liver disease in childhood/adolescence and its prevalence ranges from 7.6% to 34.2%. Since longitudinal studies of NAFLD/NASH in pediatric populations are mostly lacking, its management is extrapolated from adult studies. Beyond lifestyle modifications, the cornerstone of pediatric NAFLD treatment, numerous medications and supplements have been introduced for the management of pediatric NAFLD.
In clinical practice, diabetologists should consider NAFLD in patients with T2DM, a disease with high NAFLD prevalence and higher rates of NASH than the general population . Patients with biopsy-proven NASH and/or significant fibrosis currently qualify for pharmacotherapy. Given the variety of pharmacological agents under investigation, the therapeutic future of NAFLD seems to be promising.